Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the most common cause of dementia in the elderly. Magnetic resonance (MR) or computed tomography (CT) imaging is recommended for routine evaluation of dementias. The development of molecular imaging agents and the new techniques of MR for AD are critically important for early diagnosis, neuropathogenesis studies and assessing treatment efficacy in AD. Neuroimaging using nuclear medicine techniques such as SPECT, PET and MR spectroscopy has the potential to characterize the biomarkers for Alzheimer's disease. The present review summarizes the results of radionuclide imaging and MR imaging in AD.
PriceJLDavisPBMorrisJC: The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging12: 295–312, 1991.
6.
RamaniAJensenJHHelpernJA: Quantitative MR imaging in Alzheimer disease. Radiology241: 26–44, 2006.
7.
JackCRJrBrentleyMDTwomeyCK: MR imaging based volume measurements of the hippocampal formation and anterior temporal lobe: Validation study. Radiology176: 205–209, 1990.
8.
JackCRJrPetersenRCXuY: Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology55: 484–489, 2000.
9.
FoxNCCrumWRScahillRI: Imaging of onset and progression of Alzheimer's disease with voxel compression mapping of serial magnetic resonance images. Lancet358: 201–205, 2001.
10.
KarasGBBurtonEJRomboutsSARB: A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. Neuroimage18: 897–907, 2003.
11.
BraakEGriffingKAraiK: 1999, Neuropathology of Alzheimer's disease: What is new since A. Alzheimer?Eur Arch Psychiatry Clin Neurosci249: 14–22, 2004.
12.
RamaniAJensenJHHelpernJA: Quantitative MR imaging in Alzheimer disease. Radiology241: 26–44, 2006.
13.
BasserPJMattielloJTurnerR: Diffusion tensor echo-planar imaging of human brain. In: Proceedings of the SMRM1993: 584.
14.
KantarciKJackCRXuYC: Mild cognitive impairment and Alzheimer disease: Regional diffusivity of water. Radiology219: 101–107, 2001.
15.
StahlRDietrichOTeipelSJ: White matter damage in Alzheimer disease and mild cognitive impairment: Assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology243: 483–92, 2007.
16.
FellgiebelAWillePMullerMJ: Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: A diffusion tensor imaging study. Dement Geriatr Cogn Disord18: 101–108, 2004.
17.
CastilloMKwockLMukherjiSK: Clinical applications of proton MR spectroscopy. Am J Neuroradiol17: 1–15, 1996.
18.
ChenJGCharlesHCBarboriakDP: Magnetic resonance spectroscopy in Alzheimer's disease: Focus on N-acetylaspartate. Acta Neurol Scand Suppl176: 20–26, 2000.
19.
BruhnHFrahmJGyngellML: Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: Initial experience in patients with cerebral tumors. Radiology172: 541–548, 1989.
20.
JessenFBlockWTraberF: Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology55: 684–688, 2000.
21.
HaussingerDLaubenbergJvom DahlS: Proton magnetic resonance spectroscopy studies of human brain myoinositol in hypoosmolarity and hepatic encephalopathy. Gastroenterology107: 1475–1480, 1994.
MullinsPGRowlandLBustilloJ: Reproducibility of 1H-MRS measurements in schizophrenic patients. Mag Reson Med50, 704–707, 2003.
24.
SatlinABodickNOffenWW: Brain proton magnetic resonance spectroscopy (H.MRS) in Alzheimer's disease: Changes after treatment with xanomeline, an M1 cholinergic agonist. Am J Psychiatry154: 1459–1461, 1997.
25.
BucknerRLKelleyWMPetersenSE: Frontal cortex contributes to human memory formation. Nat Neurosci2: 311–314, 1999.
26.
BookheimerSYStrojwasMHCohenMS: Patterns of brain activation in people at risk for Alzheimer disease. N Engl J Med343: 450–456, 2000.
HarrisGJLewisRFSatlinA: Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: A promising alternative to nuclear medicine. Am J Neuroradiol19: 1727–1732, 1998.
29.
BozzaoAFlorisRBavieraME: Diffusion and perfusion MR imaging in cases of Alzheimer disease: Correlations with cortical atrophy and lesion load. Am J Neuroradiol22: 1030–1036, 2001.
30.
SilvaACWilliamsDSKoretskyAP: Evidence for the exchange of arterial spin-labeled water with tissue water in rat brain from diffusion sensitized measurements of perfusion. Magn Reson Med38: 232–7, 1997.
31.
KimST: MR Perfusion Imaging of Alzheimer's Disease with Arterial Spin Labeling (ASL). Dementia and Neurocognitive Disorders5: 1–4, 2006.
32.
JohnsonNAJahngJHWeinerMW: Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. Radiology234: 851–859, 2005.
33.
TangBNMinoshimaSGeorgeJ: Diagnosis of suspected Alzheimer's disease is improved by automated analysis of regional cerebral blood flow. Eur J Nucl Med Mol Imaging31: 1487–94, 2004.
34.
OkamuraNShinkawaMAraiH: Prediction of progression in patients with mild cognitive impairment using IMP-SPECT. Nippon Ronen Igakkai Zasshi37: 974–978, 2000.
JagustWThistedRDevousMDSr: SPECT perfusion imaging in the diagnosis of Alzheimer's disease: A clinical pathologic study. Neurology56: 950–956, 2001.
37.
IshiiKYamajiSKitagakiH: Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology53: 413–416, 1999.
38.
WalkerZCostaDCWalkerRW: Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry73: 134–40, 2002.
39.
BonteFJHarrisTSRoneyCA: Differential diagnosis between Alzheimer's and frontotemporal disease by the posterior cingulate sign. J Nucl Med45: 771–774, 2004.
40.
BrownDChisholmJAOwensJ: Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur J Nucl Med Mol Imaging30: 296–300, 2003.
41.
MegaMSDinovIDLeeL: Oribital and dorso-lateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci12: 209–218, 2000.
42.
ReimanEMChenKAlexanderGE: Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA101: 284–9, 2004.
43.
WolfeMS: The secretases of Alzheimer's disease. Curr Top Dev Biol54: 233–261, 2003.
44.
CrossA: Serotonin in Alzheimer-type dementia and other dementing illnesses. Ann N Y Acad Sci600: 405–415, 1990.
45.
CohenRM: The application of positron-emitting molecular imaging tracers in Alzheimer's disease. Mol Imaging Biol4: 204–16, 2007.
46.
TanakaN: Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: Methodology of shape analysis and its diagnostic power for Alzheimer's disease. J Cereb Blood Flow Metab21: 295–306, 2001.
47.
BohnenNI: Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol60: 1745–1748, 2003.
48.
RinneJO: Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry74: 113–115, 2003.
NordbergALundqvistHHartvigP: Kinetic analysis of regional (S)-11C-nicotine binding in normal and Alzheimer brains–in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord9: 21–7, 1995.
51.
MattsonMP: Pathways towards and away from Alzheimer's disease. Nature430: 631–9, 2004.
52.
KlunkWEEnglerHNordbergA: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol55: 306–319, 2004.
53.
KemppainenNMAaltoSWilsonIA: Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology67: 1575–80, 2006.
54.
EdisonPArcherHAHinzR: Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology68: 501–8, 2007.
55.
FaganAMMintunMAMachRH: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol59: 512–9, 2006.
56.
PikeKESavageGVillemagneVL: ß-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain130: 2837–2844, 2007.
57.
SmallGWKepeVErcoliLM: PET of Brain Amyloid and Tau in Mild Cognitive Impairment. New Engl J Med355: 2652–2663, 2006.
58.
VerhoeffNP: In-vivo imaging of Alzheimer disease betaamyloic with [11C]SB-13 PET. Am J Geriatr Psychiatry12: 584–595, 2004.
59.
MathisCALoprestiBJKlunkWE: Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol34: 809–22, 2007.
60.
KadirAAndreasenNAlmkvistO: Effect of phenserine treatment on brain functional activity and amyloid in AD. Ann Neurol63: 621–631, 2008.
61.
McMahonPMArakiSSSandbergEA: Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology228: 515–22, 2003.
62.
IshiiKMinoshimaS: PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease. Eur J Nucl Med Mol Imaging32: 1463–5, 2005.
